GDRXHealthcare · Health Information ServicesThe 15 Wall Street analysts covering GoodRx Holdings, Inc. hold a median 12-month price target of $4 — +17.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 17 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores GoodRx Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GDRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +17.6% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Aug 2026 | Barclays | Maintains | Underweight | $3.00 → $4.00 |
| 13 Aug 2026 | UBS | Maintains | Neutral | — |
| 13 Aug 2026 | UBS | Maintains | Neutral | $2.50 → $3.75 |
| 11 Aug 2026 | Citigroup | Maintains | Buy | — |
| 11 Aug 2026 | Citigroup | Maintains | Buy | $4.00 → $5.00 |
| 11 Aug 2026 | TD Cowen | Maintains | Buy | $4.00 → $5.00 |
| 11 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $3.50 → $5.00 |
| 14 May 2026 | Citigroup | Maintains | Buy | — |
| 14 May 2026 | Citigroup | Maintains | Buy | $3.50 → $4.00 |
| 11 May 2026 | TD Cowen | Maintains | Buy | $3.00 → $4.00 |
| 11 May 2026 | TD Cowen | Maintains | Buy | — |
| 4 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 3 Mar 2026 | Citigroup | Maintains | Buy | — |
| 2 Mar 2026 | Goldman Sachs | Maintains | Neutral | — |
| 27 Feb 2026 | JP Morgan | Downgrade | Neutral | — |
| 27 Feb 2026 | Mizuho | Maintains | Neutral | — |
| 22 Jan 2026 | Jefferies | Downgrade | Hold | — |
| 9 Jan 2026 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GDRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 17 Sept 2026, GoodRx Holdings, Inc. returned −17.1% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 12% of US stocks
Cheaper than 60% of US stocks
Cheaper than 49% of US stocks
Cheaper than 28% of US stocks
Higher than 25% of US stocks
Higher than 15% of US stocks
Higher than 96% of US stocks
Higher than 67% of US stocks
Higher than 52% of US stocks
Higher than 49% of US stocks
Higher than 65% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
GoodRx Holdings, Inc. has a market value of $1.2B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 June 2026: $785.2M. The latest quarter shrank 1.3% year on year.
Net income over the same four quarters: $16.2M, a 2.1% net margin.
Diluted earnings per share, trailing twelve months: $0.05.
Free cash flow in the twelve months to 30 June 2026: $131.7M, after $65.4M of capital spending.
GoodRx Holdings, Inc. spent $85.0M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 56.5×; forward P/E: 9.5× — the forward figure prices analyst consensus estimates, not reported earnings.
GoodRx Holdings, Inc. employs 697 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GoodRx Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
GoodRx has launched a new prescription plan covering a primary member and up to four dependents, including children, adult family members, and pets, according to a Sept. 3 press release.
Why it matters — This expansion widens GoodRx's potential customer base and could increase its reach within households, which is relevant to its growth outlook.
GoodRx announced a family healthcare subscription providing access to common medical services and over 250 medications, with plans to launch the program as part of employer health benefits in 2027.
Why it matters — A GDRX watcher would care because this new subscription and planned employer-benefit rollout could expand GoodRx's reach and revenue streams beyond its existing prescription savings model.
GoodRx launched the GoodRx Companion Family Plan, expanding its healthcare subscription offering to cover the entire household, including pets, by bundling free and low-cost prescriptions with savings on common healthcare services. The launch comes as rising out-of-pocket costs and coverage gaps place more financial strain on households.
Why it matters — This product expansion broadens GoodRx's addressable market and subscription appeal to full households, potentially supporting engagement and retention.
GoodRx's stock has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. Direct brand launches and new subscription plans have contributed to the recent positive developments, though the author remains only marginally more positive and notes considerable risk, keeping a neutral rating.
Why it matters — A GDRX watcher would care because the stock's recovery and new product initiatives signal improving momentum, even as the analyst maintains a cautious, neutral stance due to remaining risk.
GoodRx CEO Wendy Barnes discussed the company's partnership with TrumpRx and its efforts to lower prescription drug costs in an interview on Fox Business' "The Claman Countdown." The discussion centered on the push for competitive cash pricing for prescription drugs.
Why it matters — The TrumpRx partnership and pricing initiatives reflect GoodRx's efforts to expand its role in lowering prescription drug costs, which is central to its business model.
The 15 Wall Street analysts covering GoodRx Holdings, Inc. have a median 12-month price target of $4, with estimates ranging from $2.65 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering GoodRx Holdings, Inc., 5 rate it a Buy, 8 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks GoodRx Holdings, Inc. 78 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Sept 2026, GoodRx Holdings, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +17.6% from the last close, and Ticker Nerd's factor model ranks GoodRx Holdings, Inc. 78 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering GoodRx Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GDRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.65 to $5 over the next 12 months.
GoodRx Holdings, Inc. returned -17.1% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
GoodRx Holdings, Inc. Class A Common Stock represents ownership in GoodRx, a consumer-focused digital healthcare company that helps U.S.
The most recent item we track (PYMNTS, 4 Sept 2026): "GoodRx Covers Whole Households and Pets in New Prescription Plan". GoodRx has launched a new prescription plan covering a primary member and up to four dependents, including children, adult family members, and pets, according to a Sept. 3 press release.
GoodRx Holdings, Inc. Class A Common Stock represents ownership in GoodRx, a consumer-focused digital healthcare company that helps U.S. consumers compare prescription drug prices and access savings tools. GoodRx provides a price comparison platform with geographically relevant pharmacy pricing, discount codes, and prescription transaction services designed to make medication costs more transparent. The company also offers telehealth services, subscription products, and pharma manufacturer solutions that support patients, pharmacies, healthcare professionals, payers, and pharmaceutical partners. Its platform is used across the prescription marketplace to connect users with retail pharmacies and medication savings resources. Headquartered in Santa Monica, California, GoodRx operates primarily in the U.S. healthcare market, where it plays a role in digital prescription savings, healthcare information, and patient access services.
CEO Ms. Wendy Barnes · 697 employees · United States · https://www.goodrx.com
